TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Authors
Keywords
-
Journal
OncoImmunology
Volume -, Issue -, Pages e1466769
Publisher
Informa UK Limited
Online
2018-05-24
DOI
10.1080/2162402x.2018.1466769
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
- (2018) Karolina Woroniecka et al. CLINICAL CANCER RESEARCH
- Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis
- (2017) Enshan Feng et al. EUROPEAN NEUROLOGY
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
- (2017) Nicholas A. Manieri et al. TRENDS IN IMMUNOLOGY
- Biomarkers and Immunotherapeutic Targets in Glioblastoma
- (2017) Alice L. Hung et al. World Neurosurgery
- Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane
- (2017) Ravi Kumar et al. PLoS One
- Survival in glioblastoma: a review on the impact of treatment modalities
- (2016) P. D. Delgado-López et al. Clinical & Translational Oncology
- T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
- (2016) Y. Kong et al. CLINICAL CANCER RESEARCH
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy
- (2016) Xin-guang Liu et al. IMMUNOLOGICAL INVESTIGATIONS
- Roles of regulatory T cells in cancer immunity
- (2016) Yoshiko Takeuchi et al. INTERNATIONAL IMMUNOLOGY
- Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression
- (2016) Takeshi Nakahara et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis
- (2015) Katia R M Leite et al. Diagnostic Pathology
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes
- (2015) Baisakhi Raychaudhuri et al. JOURNAL OF NEURO-ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- PD-L1 expression and prognostic impact in glioblastoma
- (2015) Edjah K. Nduom et al. NEURO-ONCOLOGY
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
- (2015) Tao Qin et al. Oncotarget
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model
- (2014) Michael Chae et al. NEURO-ONCOLOGY
- Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
- (2014) Zineb Belcaid et al. PLoS One
- Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR
- (2013) Noa Stanietsky et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Role of tumor-infiltrating CD11b+ antigen-presenting cells in the progression of gastric cancer
- (2013) Yoshihiro Okita et al. JOURNAL OF SURGICAL RESEARCH
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy
- (2012) Z.-C. Ding et al. BLOOD
- Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer
- (2012) Sandra Salvi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
- (2012) A. Facciabene et al. CANCER RESEARCH
- Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients
- (2012) Fu-Jun Li et al. IMMUNOLOGY LETTERS
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
- (2012) Xin Gao et al. PLoS One
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via L-Arginine Metabolism
- (2009) L. A. Norian et al. CANCER RESEARCH
- Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth
- (2009) Albert Lin et al. IMMUNOLOGY LETTERS
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
- Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors
- (2008) Joannes F.M. Jacobs et al. NEURO-ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now